Nektar Therapeutics

Nektar Therapeutics will announce top-line data from the 16-week induction period of its global Phase 2b REZOLVE-AD trial on June 24, 2025.

• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.

Mural Therapeutics has terminated its lead IL-2 program nemvaleukin after the candidate failed to meet clinical endpoints, forcing the company to reduce its workforce by 90%.

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Nektar Therapeutics and TrialNet have announced a collaboration to evaluate rezpegaldesleukin, a first-in-class T regulatory cell stimulator, in patients with new-onset type 1 diabetes.

The FDA has granted Fast Track designation to rezpegaldesleukin for moderate-to-severe atopic dermatitis in patients 12 years and older.

Nektar Therapeutics' NKTR-255, an IL-15 agonist, significantly improved complete response rates (CRR) in lymphoma patients after CAR-T therapy.

• The 7th Treg-Directed Therapies Summit, scheduled for March 2025 in Boston, will bring together leading biotech companies and academic institutions to discuss breakthroughs in regulatory T cell therapy development. • Recent strategic partnerships between major players like Quell-AstraZeneca and Parvus-AbbVie have accelerated innovation in Treg-based treatments for autoimmune and inflammatory conditions. • The summit will feature presentations from prominent organizations including Abata Therapeutics, Harvard Medical School, and Nektar Therapeutics, focusing on clinical data and therapeutic advancement strategies.

NKTR-255, combined with durvalumab, demonstrates potential in treating radiation-induced lymphopenia in locally advanced NSCLC patients undergoing chemoradiation.

Nektar's NKTR-255, combined with durvalumab, significantly improved lymphocyte recovery in NSCLC patients after chemoradiation, compared to historical controls.